Kura Oncology, Inc. (KURA) is a San Diego-based precision oncology company. Its first commercial product, KOMZIFTI (ziftomenib), is an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia; the company is also developing darlifarnib and early-stage menin programs in metabolic disease.
Shares changed hands at $7.46 in Tuesday's session, up $0.37 or 5.22% from the previous close of $7.09. The direction was unambiguously higher, with the stock gapping up to $7.68 at the open before giving back part of that advance and firming again in the afternoon. No single fundamental release explained the full move; the verified drivers were a public insider purchase, live management commentary at an investor conference, and a rebound from deeply oversold levels.
The most concrete catalyst arrived in a Form 4 filed after Monday's close. Wilson bought 98,881 shares on Nov. 13 at a volume-weighted average of $7.63 and another 101,119 shares on Nov. 16 at an average of $7.42 — roughly 200,000 shares for about $1.50 million. He now holds 635,456 shares directly.
The signal mattered because of timing. Those purchases landed within days of the stock touching $6.75, its lowest level in a year, and on the same day a bearish research take circulated arguing that the company's remaining cash is largely committed to its frontline trial. For a company with a market capitalization of roughly $685 million, a CEO buying about $1.5 million of stock at prevailing prices is small in dollar terms but large as a statement of conviction, and the shares had already begun firming in overnight trading before the opening bell.
Management also presented at the UBS Global Biopharma conference in London at 8:20 a.m. ET. Comments from Chief Commercial Officer Brian Powl and Chief Medical Officer Mollie Leoni focused on three points: refills are growing faster than new starts, which implies patients are staying on therapy longer than the launch cohort suggested; roughly half of NPM1-mutated patients also carry FLT3 mutations, making combination therapy the key to expanding the addressable population; and the company remains aligned with the FDA on a roughly 40-patient registrational study of darlifarnib in HRAS-mutant salivary gland cancer.
Investors also pressed management on the competitive overhang. The team argued that KOMZIFTI's tolerability and combinability remain differentiators, particularly in the frontline setting where the Phase 3 KOMET-017 program is enrolling. That rebuttal matters because J&J's bleximenib data was the direct cause of the recent collapse.
Tuesday's gain is best read against a violent two-week drawdown. On Nov. 4, shares fell about 23% after an ASH abstract showed JNJ's bleximenib posting higher complete remission rates than KOMZIFTI in relapsed disease, prompting analysts to label it a credible threat. The stock slid further to $6.75 on Nov. 6, bounced mid-month, then dropped 8.75% on Monday. Tuesday's advance recovers only a fraction of that damage.
Third-quarter results, reported Nov. 10, provided the fundamental floor: KOMZIFTI net product revenue of $13.9 million, up 53% sequentially; about 2,400 total prescriptions, up 65%; 170 prescribing accounts; an adjusted loss of $0.78 per share versus a $0.81 consensus; and $492.1 million in cash, supplemented by a strategic financing arrangement with Oberland Capital. Revenue of $22.83 million missed the $24.86 million estimate, and sell-side coverage remains overwhelmingly constructive, with Barclays at $28, UBS and Citizens at $24, and TD Cowen and Citi at Buy or Market Outperform. Consensus targets sit in the mid-$20s.
Volume was solid but not exceptional. Roughly 2.2 million shares had traded by late afternoon against a three-month average near 2.14 million, so participation was in line with normal levels rather than signaling an institutional scramble. The advance ran directly against the sector: the SPDR S&P Biotech ETF and the large-cap biotech benchmark both slipped about 0.6% to 0.7%.
Technically, the move lifted the shares back above the prior session's close but left them below the $7.75 intraday high and well under the 20-day trend, with the $6.75 low now serving as the reference floor. The stock remains down roughly 28% year to date and about 46% below its August peak of $13.90.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price move. Kura Oncology earns 30 out of 100.
The verified news was modest: an insider purchase and conference commentary do not change revenue forecasts or de-risk the pipeline. The move itself was notable but not extreme — 5.22% is about 1.6 times the stock's typical daily swing of roughly 3.2%, and moves of this size or larger occurred 14 times in the last 60 sessions. Modest news plus a routine-sized move produce the score.
Attention now turns to the American Society of Hematology meeting in December, where eight ziftomenib abstracts — four of them oral — will include the first clinical data on combining ziftomenib with FLT3 inhibitors in both newly diagnosed and relapsed disease. Management will also present at the Jefferies Global Healthcare Conference on Nov. 18, and darlifarnib's IND submission is targeted by year-end, with the registrational salivary gland study slated for the first half of 2027.
Fourth-quarter and full-year results are expected in early March 2027, and investors will watch whether KOMZIFTI revenue growth holds above the 50% sequential pace and whether refill trends stabilize. Key risks include continued share loss to bleximenib, a revenue base that still trails consensus, heavy cash consumption against roughly $492 million in reserves, potential dilution or additional financing, and the binary nature of clinical readouts in a competitive AML field.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list offers a practical snapshot of what is actually working in today's tape rather than a static model portfolio. For investors navigating volatile small-cap biotech names, reviewing the current leaders is a useful next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The RSI Indicator for KURA moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 31 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In 64 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for KURA entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.354) is normal, around the industry mean (3.592). P/E Ratio (-2.157) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of biopharmaceutical services
Industry Biotechnology